A 30-year-old woman developed veno-occlusive disease of the liver during an allogeneic BMT for acute leukemia. Treatment with recombinant human tissue plasminogen activator and heparin resulted in an incomplete and transient response followed by progressive disease. The patient was then given defibrotide (DF), a mammalian tissue-derived polydeoxyribonucleotide developed for the treatment of a number of vascular disorders, which has thrombolytic and anti-thrombotic properties. No significant bleeding or other major toxicities were observed during treatment and she made a full recovery. At 6 months after the onset of VOD her liver function tests and color flow Doppler ultrasound scan are normal. Our experience supports the preliminary results already obtained with DF. Its efficacy should be evaluated in a prospective randomized fashion.
Hepatic veno-occlusive disease (VOD) is a major conditioning regimen-related toxicity associated with hematopoietic stem cell transplantation, being uniformly fatal when severe. [1] [2] [3] Although the treatment of liver VOD is primarly supportive, with careful management of fluid overload and adoption of measures to preserve respiratory and renal function, promising results have been obtained with the combination of recombinant human tissue plasminogen activator (rh-tPA) and heparin. 4, 5 However, this is associated with a potential risk of serious hemorrhagic complications in this patient population and its use is usually restricted to patients whose risk of dying of VOD exceeds 20 to 50%. 5, 6 Other methods of treating VOD are needed and a new approach is the use of defibrotide (DF). This is an adenosine-receptor agonist extracted from mammalian organs, with anti-thrombotic and thrombolytic activities and no systemic anti-coagulant activity, giving it a potential theraCorrespondence: MM Abecasis, BMT Unit, Instituto Português de Oncologia, R Prof Lima Basto 1093, Lisboa Codex, Portugal Received 1 September 1998; accepted 12 November 1998 peutic advantage over the combination of rh-tPA and heparin. DF has several activities that may be relevant to the treatment of VOD: it decreases plasminogen activator inhibitor levels (PAI-1), increases tPA function and stimulates thrombomodulin synthesis. 7 Its successful use in this context has recently been reported. 8 We describe a patient with acute lymphoblastic leukemia who developed liver VOD, refractory to rh-tPA and heparin, and in whom a complete response was obtained after treatment with DF.
Case report
A 30-year-old woman, diagnosed as having ALL with t(4;11) in July 1997 was referred for allogeneic BMT in first remission in January 1998. On admission for BMT the liver was not enlarged, liver function tests were normal as was an abdominal color-flow Doppler ultrasound scan (US). She was IgG-positive for Epstein-Barr virus and cytomegalovirus but serologic tests were negative for hepatitis A, B and C.
She underwent allogeneic BMT with an HLA-identical sister as a donor, after conditioning with busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg). Prophylaxis for GVHD consisted of short course MTX and cyclosporine.
On day +20, she began to experience right upper quadrant abdominal pain and tenderness followed by significant weight gain and ascites. An abdominal color-flow Doppler US showed hepatomegaly, ascites and a marked reduction in portal vein blood flow. The total serum bilirubin rose from 0.6 mg/dl to 5.4 mg/dl, the serum creatinine from 0.7 mg/dl to 1.8 mg/dl over the initial 96-h period. Percent weight gain from baseline was 7%.
Her clinical condition continued to deteriorate and by day +29 rh-tPA was administered at a dose of 20 mg/day by 4-h infusion, and given on each of 4 consecutive days. Heparin was also administered as a bolus of 1000 U at the start of rh-tPA and continued by constant infusion at a dose of 150 U/kg/day for 10 days.
During treatment her serum bilirubin rose to 11 mg/dl by day +33, and decreased to a nadir of 4 mg/dl by day +60 (3 weeks after the end of rh-tPA and heparin). Serial colorflow Doppler US using a Siemens Sonoline Elegra ultrasound machine (Germany) were performed to follow the course of the disease. One week after the start of rh-tPA By day +64 it was obvious that she had progressive VOD, with rising bilirubin (5.4 mg/dl) and D-dimer levels (5185 ng/ml), a consistent color-flow Doppler US (hepatomegaly, ascites and a marked reduction of the portal vein flow), and deteriorating clinical condition with increasing weight and frequent paracentesis needed to relieve tense ascites. No additional treatment changes were made and DF was administered at an initial dose dose of 20 mg/kg/day (increased to 40 mg/kg/day after 5 days), in four divided doses, each given as a 2-h intravenous infusion for 20 days. No significant toxicities attributable to its use were observed during treatment. The patient made a remarkable recovery and was discharged on day +86. Ten days after the end of treatment the serum bilirubin was 1.1 mg/dl and the Doppler US showed no signs of impaired blood flow in the portal and hepatic veins (Figure 3 ). At 8 months after the onset of liver VOD she is in excellent clinical condition and has normal liver function tests.
Discussion
Endothelial damage of the centrilobular sinusoids and terminal hepatic venules caused by conditioning therapy is now believed to be the main event in the pathogenesis of VOD. This endothelial injury not only triggers the coagulation cascade and induces deposition of fibrinogen and factor VIII in the subendothelium of the affected vessels, but also stimulates deposition of extracellular matrix in liver sinusoids, probably by stellate cells, ultimately leading to fibrosis of centrilobular sinusoids and necrosis of zone 3 hepatocytes. 9, 10 Clinical trials aimed at preventing these lesions have met with mixed results (reviewed in Ref.
2). More recently, investigators have sought to reverse established VOD with thrombolytic therapy. In the largest published series, Bearman et al 5 used rh-tPA and heparin to treat 42 patients with VOD, including 10 with established severe disease. Treatment was successful in 12 patients (29%); however, 37 had bleeding complications during or after treatment that were severe in 10 and fatal in four. Multiorgan failure before the start of treatment was the major prognostic factor for a poor response as no patients on dialysis or mechanical ventilation responded. 5 Clearly, other approaches to the treatment of VOD are needed and a potential new medical approach has been recently reported by Richardson et al. 8 They used DF to treat 19 patients with VOD who had over 40% risk of severe disease based on the prediction model developed by Bearman et al, or who had severe late onset disease not addressed by this model. 6 Seven of the 19 patients had failed to respond to treatment with rh-tPA and heparin and all patients had renal impairment and/or an oxygen require- ment. Eight had a complete response, defined as reduction in bilirubin to less than 2 mg/dl with improvement in VODrelated symptoms, and six of these patients also had resolution of their multiorgan impairment. In none of the 19 treated patients were significant treatment-related toxicities observed.
Our patient had a late occurrence of VOD (day +20), and experienced only a partial and transient response to thrombolytic therapy. Three weeks after stopping this treatment she again had evidence of progressive VOD, with rising bilirubin and D-dimer levels and a consistent Doppler US. 11, 12 We did not consider a second course of rh-tPA and heparin since there is evidence that this unacceptably increases the risk of hemorrhage, and the likelihood of response is small. 13, 14 Instead, we decided to use DF and a complete response was achieved. Defibrotide (Crinos Farmacobiologica, Como, Italy) is prepared by controlled depolymerization of deoxyribonucleic acid obtained from mammalian organs and has been developed for the treatment of a number of vascular disorders. Its mechanisms of action are still to be fully elucidated but available data indicate that it has a number of effects on endothelial and blood components involved in hemostasis. It stimulates prostaglandin I 2 and E 2 production, reduces leukotriene B 4 levels, and also increases the function of t-PA and decreases PAI-1 activity, thereby stimulating fibrinolysis. Preliminary data suggest that some of these actions may be mediated by interaction with adenosine receptors. It is largely devoid of major anticoagulant activity, but it may have some inhibitory effects on platelet function. 7 It is highly unlikely that this patient's improvement was due to the previous treatment alone, since most patients who respond to thrombolytic therapy do so within the first 48 to 96 h. 5 Although we cannot rule out the possibility that she would have improved without DF treatment, in the Seattle experience only two of the 30 patients who did not respond to rh-tPA and heparin survived beyond 100 days post-transplant. 5 One can also speculate that the initial administration of thrombolytic therapy may have facilitated a favorable response to DF. This may also be the case in the series of Richardson et al 8 where five of the seven patients previously treated with rh-tPA responded to DF, as opposed to only three of 12 not receiving thrombolytic therapy. However, both subgroups of patients in this report are too small to analyze for factors predicting response to DF. A better understanding of the mechanisms of action of DF may also clarify this point.
In conclusion, the preliminary results of DF look very promising and its efficacy in the treatment of liver VOD requires evaluation in a prospective randomized fashion.
